[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

PE20061036A1 - SODIUM CHANNEL BLOCKERS, TETRODOTOXIN OR SAXITOXIN, AS AGENTS FOR THE TREATMENT OF NICOTINE DEPENDENCE - Google Patents

SODIUM CHANNEL BLOCKERS, TETRODOTOXIN OR SAXITOXIN, AS AGENTS FOR THE TREATMENT OF NICOTINE DEPENDENCE

Info

Publication number
PE20061036A1
PE20061036A1 PE2006000160A PE2006000160A PE20061036A1 PE 20061036 A1 PE20061036 A1 PE 20061036A1 PE 2006000160 A PE2006000160 A PE 2006000160A PE 2006000160 A PE2006000160 A PE 2006000160A PE 20061036 A1 PE20061036 A1 PE 20061036A1
Authority
PE
Peru
Prior art keywords
sodium channel
saxitoxin
tetrodotoxin
treatment
agents
Prior art date
Application number
PE2006000160A
Other languages
Spanish (es)
Inventor
Helmut Henrich Buschmann
Hernandez Jose Miguel Vela
Gomis Antonio Farre
Original Assignee
Esteve Labor Dr
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP05384001A external-priority patent/EP1690541A1/en
Priority claimed from EP05384002A external-priority patent/EP1714655A1/en
Application filed by Esteve Labor Dr filed Critical Esteve Labor Dr
Publication of PE20061036A1 publication Critical patent/PE20061036A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/465—Nicotine; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/529—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

REFERIDA A UN BLOQUEADOR DEL CANAL DE SODIO TAL COMO LA TETRODOTOXINA O SAXITOXINA, SUS ANALOGOS Y DERIVADOS ASI COMO SUS SALES FISIOLOGICAMENTE ACEPTABLES, LAS CUALES SON UTILES EN EL TRATAMIENTO DE LA DEPENDENCIA DE LA NICOTINA. TAMBIEN ESTA REFERIDA A UNA COMBINACION QUE COMPRENDE UNA SUSTANCIA A, LA CUAL ES UN BLOQUEADOR DEL CANAL DE SODIO, Y UNA SUSTANCIA B QUE SE SELECCIONA DE NICOTINA O SUS DERIVADOS. DICHA COMBINACION PUEDE ESTAR BAJO LA FORMA DE PARCHE, GOMA DE MASCAR, SPRAY NASAL, INHALADOR, ENTRE OTROSREFERRING TO A SODIUM CHANNEL BLOCKER SUCH AS TETRODOTOXIN OR SAXITOXIN, ITS ANALOGS AND DERIVATIVES AS WELL AS THEIR PHYSIOLOGICALLY ACCEPTABLE SALTS, WHICH ARE USEFUL IN THE TREATMENT OF NICOTINE DEPENDENCE. IT ALSO REFERS TO A COMBINATION THAT INCLUDES A SUBSTANCE A, WHICH IS A SODIUM CHANNEL BLOCKER, AND A SUBSTANCE B THAT IS SELECTED FROM NICOTINE OR ITS DERIVATIVES. SUCH COMBINATION MAY BE IN THE FORM OF A PATCH, CHEWING GUM, NASAL SPRAY, INHALER, AMONG OTHERS

PE2006000160A 2005-02-11 2006-02-10 SODIUM CHANNEL BLOCKERS, TETRODOTOXIN OR SAXITOXIN, AS AGENTS FOR THE TREATMENT OF NICOTINE DEPENDENCE PE20061036A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP05384001A EP1690541A1 (en) 2005-02-11 2005-02-11 Use of a sodium channel blocker and their analogues for the treatment of nicotine dependency
EP05384002A EP1714655A1 (en) 2005-04-22 2005-04-22 Use of sodium channel blockers and their analogues for the treatment of nicotine dependency

Publications (1)

Publication Number Publication Date
PE20061036A1 true PE20061036A1 (en) 2006-11-24

Family

ID=36636342

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2006000160A PE20061036A1 (en) 2005-02-11 2006-02-10 SODIUM CHANNEL BLOCKERS, TETRODOTOXIN OR SAXITOXIN, AS AGENTS FOR THE TREATMENT OF NICOTINE DEPENDENCE

Country Status (6)

Country Link
EP (1) EP1853268A1 (en)
AR (1) AR053811A1 (en)
CA (1) CA2597101A1 (en)
PE (1) PE20061036A1 (en)
TW (1) TW200640463A (en)
WO (1) WO2006084765A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201602576D0 (en) 2016-02-12 2016-03-30 Bergen Teknologioverforing As Process

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69529156T2 (en) * 1994-03-17 2003-09-25 Nanning Maple Leaf Pharmaceutical Co., Ltd. USE OF AMINO-HYDROGENATED CHINAZOLINE COMPOUNDS AND THEIR DERIVATIVES FOR BODYING IN DRUG ADDICTION
CN1284536C (en) * 2000-09-18 2006-11-15 威克斯医药有限公司 Antalgic method by general medicine application

Also Published As

Publication number Publication date
WO2006084765A1 (en) 2006-08-17
CA2597101A1 (en) 2006-08-17
AR053811A1 (en) 2007-05-23
EP1853268A1 (en) 2007-11-14
TW200640463A (en) 2006-12-01

Similar Documents

Publication Publication Date Title
ECSP13012385A (en) AGONIST HETEROCYCLIC COMPOUNDS OF THE IP RECEIVER
HN2006007884A (en) OXYINDOL DERIVATIVES
GT200800187A (en) TETRAHYDROPIRIDOTIENOPIRIMIDINE COMPOUNDS AND PROCEDURES FOR THE SAME USE
ECSP12012171A (en) PHARMACEUTICAL COMPOSITIONS OF THE ESPIRO-OXINDOL COMPOUND FOR TOPICAL ADMINISTRATION AND ITS USES AS THERAPEUTIC AGENTS
GT200600028A (en) COMPOUNDS AND COMPOSITIONS AS INHIBITORS OF PROTEINA KINASA
NI201000193A (en) ORAL FORMULATIONS OF CITIDINE ANALOGUES AND METHODS OF USE OF THE SAME.
CR9475A (en) AMINA DERIVATIVES SUBSTITUTED AS PROTEIN KINASA INHIBITORS
CR10327A (en) "PIRIDIN (3-4-b) PIRAZINONAS"
GT200500325A (en) PIRAZOLO-PIRIMIDINAS 1,4-REPLACED AS QUINASA INHIBITORS
ECSP12011631A (en) PROLONGED INSULIN COMPOSITION
EA200701065A1 (en) INJECTABLE COMPOSITIONS CONTAINING NANODISPERS Olanzapine
ECSP088208A (en) NEW MACROCYCLIC INHIBITORS OF HEPATITIS C VIRUS REPLICATION
CR20110578A (en) INHIBITORS OF THE EXTERNAL RENAL MEDULAR POTASSIUM CHANNEL
ECSP066972A (en) MUTUAL PROMOTES OF GLUCOSAMINE AND GLUCOSAMINE / ANTI-INFLAMMATORY, COMPOSITIONS, AND METHODS
CL2011000835A1 (en) Compounds derived from spiro-oxindole; sodium channel modulators; pharmaceutical composition comprising said compound; and use in the treatment of pain, depression, cardiovascular, respiratory, psychiatric diseases, among others.
UY30477A1 (en) DERIVATIVES OF [4,5 '] BIPIRIMIDINIL-6,4´-DIAMINE AS PROTEIN KINASE INHIBITORS
ATE474561T1 (en) ORODISPERSIBLE PHARMACEUTICAL COMPOSITION FOR ORAL, OROMUCOSAL OR SUBLINGUAL ADMINISTRATION OF AGOMELATIN
NO20075111L (en) Pharmaceutical composition
CR11264A (en) COMPOUNDS OF 5- (4-HALO-ALCOXI) -PENYL) -PIRIMIDIN-2-AMINA AND COMPOSITIONS AS KINASE INHIBITORS
CL2017003066A1 (en) Compositions of amorphous calcium carbonate for administration by inhalation, sublingual or buccal
UY30723A1 (en) SUBSTITUTED BICICLOCARBOXYAMIDE COMPOUNDS
CR11065A (en) WEEKLY ADMINISTRATION OF DIPEPTIDILO PEPTIDASE INHIBITORS
UY31780A (en) REPLACED PHENOXIBENZAMIDS
UY30534A1 (en) DERIVATIVES OF 5,6-BISARIL-2-PIRIDIN-CARBOXAMIDE, ITS PREPARATION AND ITS APPLICATION IN THERAPEUTICS AS ANTAGONISTS OF UROTENSIN II RECEPTORS
AR101236A1 (en) COMPOSITIONS FOR ORAL CARE

Legal Events

Date Code Title Description
FC Refusal